AB Science
Clinical trials sponsored by AB Science, explained in plain language.
Develops small-molecule kinase inhibitors for cancer and inflammatory diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New hope for tough leukemia? early trial tests AB8939
Disease control Recruiting nowThis early-phase trial is testing a new drug called AB8939, given daily through a vein, for people with acute myeloid leukemia that has come back or not responded to standard treatments. About 78 participants will receive AB8939, sometimes with another drug called venetoclax. The…
Phase 1/2 • Sponsor: AB Science • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Hope for ALS patients: new drug combo enters final testing phase
Disease control Recruiting nowThis Phase 3 trial is testing whether adding masitinib to the standard ALS drug riluzole can slow the disease better than riluzole alone. About 495 people with ALS will take either masitinib or a placebo, plus riluzole, and researchers will track changes in muscle function, breat…
Phase 3 • Sponsor: AB Science • Aim: Disease control
Last updated Jun 26, 2026 16:03 UTC